From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea.

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Halifax Group ("Halifax"), a middle market private equity firm that partners with management to invest in market-leading ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

DelveInsight's "VUITY Market Size, Forecast, and Market Insight Report" highlights the details around VUITY, which is a ...

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

Pharmaceutical giants are hitting the brakes on major mergers and acquisitions. Bankers point to President Donald Trump’s unpredictable ...

By hoodwinking seniors into private Medicare Advantage plans, insurers profit by denying care and bankrupting hospitals.

RIT gives Alfred Davis Awards to a teacher and student for their work on campus and volunteerism in the community.

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older ...

Rebranding efforts include a new logo, overall brand presence, and corporate design.

DelveInsight's "ROCKLATAN/ROCLANDA Market Size, Forecast, and Market Insight Report" highlights the details around ...